For instance, patients with high TMPRSS2 expression in PCa may benefit from therapies that enhance immune infiltration, while those with low TMPRSS2 levels in LUAD might require alternative approaches to improve treatment responses. The gene discussed is TMPRSS2; the disease is posterior cortical atrophy.